Keyphrases
Heart Failure
100%
Atrial Fibrillation
56%
Nationwide Registry
42%
Myocardial Infarction
42%
Heart Failure Risk
39%
Thromboembolic Risk
39%
Copenhagen
39%
Risk Study
39%
Pulmonary Embolism
31%
N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
28%
High Risk
28%
Venous Thromboembolism
27%
Renal Function
27%
Randomized Clinical Trial
26%
Left Atrial Appendage
26%
Cardiotoxicity
26%
Patients with Cancer
26%
COVID-19
26%
National Cohort Study
26%
Percutaneous Left Atrial Appendage Occlusion
26%
Women with Breast Cancer
26%
Cardiovascular Disease in Women
26%
Cancer-associated Thrombosis
26%
Natriuretic Peptides
26%
Plasma Concentration
23%
Cardiovascular Disease
22%
Low Molecular Weight Heparin
21%
Mineralocorticoid Receptor Antagonists
19%
Confidence Interval
19%
Chronic Kidney Disease
19%
Atrial Natriuretic Peptide
19%
Diabetes
19%
Echocardiography
18%
Oral Anticoagulant Therapy
18%
Left Ventricular Ejection Fraction
18%
Left Ventricular Systolic Function
17%
Registry Study
17%
Heart Disease Diagnosis
17%
Infection-related
17%
Left Ventricular Strain
16%
Clinical Practice
16%
Breast Cancer
15%
Anticoagulant Treatment
14%
Heart Failure with Preserved Ejection Fraction (HFpEF)
14%
Obesity
14%
Rehospitalization
14%
Elderly Outpatients
13%
Breast Cancer Diagnosis
13%
Acral Ischemia
13%
Capecitabine
13%
Medicine and Dentistry
Heart Failure
52%
Atrial Fibrillation
52%
Thromboembolism
29%
Venous Thromboembolism
29%
Pulmonary Embolism
28%
Infection
26%
Cardiovascular Disease in Women
26%
Breast Cancer
26%
Malignant Neoplasm
23%
Cardiovascular Disease
22%
Systolic Function
21%
Mineralocorticoid Antagonist
19%
Apoplexy
18%
Prevalence
17%
Anticoagulant Therapy
16%
Chronic Kidney Disease
16%
Echocardiography
16%
Antithrombotic
16%
Heart Function
14%
Heart Failure with Reduced Ejection Fraction
14%
Symptom
13%
Systolic Dysfunction
13%
Ischemia
13%
Oncologist
13%
Sarcoma
13%
Observational Study
13%
Aquagenic Pruritus
13%
Cerebral Hemorrhage
13%
Androgen
13%
Attitude
13%
Cardiology
13%
Ejection Fraction
13%
Combination Therapy
13%
Patient with Type 2 Diabetes
13%
COVID-19
13%
Gangrene
13%
Concurrent Infection
13%
Phlebothrombosis
13%
Cardiotoxicity
13%
Drug Megadose
13%
Coronavirinae
13%
Heart Valve Surgery
13%
Left Bundle Branch Block
13%
Microthrombus
13%
Doxorubicin
13%
Population Risk
13%
Randomized Clinical Trial
13%
Virus Infection
13%
Selective Serotonin Reuptake Inhibitor
13%
Paroxetine
13%
Pharmacology, Toxicology and Pharmaceutical Science
Atrial Fibrillation
73%
Heart Failure
60%
Thromboembolism
42%
Venous Thromboembolism
42%
Anticoagulant Agent
41%
Heart Infarction
29%
Lung Embolism
28%
Infection
28%
Natriuretic Factor
26%
Cardiotoxicity
26%
Atrial Natriuretic Factor
22%
Malignant Neoplasm
21%
Chronic Kidney Failure
18%
Bleeding
18%
Low Molecular Weight Heparin
17%
Cardiovascular Disease
16%
Cohort Study
14%
Combination Therapy
14%
Heart Failure with Reduced Ejection Fraction
14%
Breast Cancer
14%
Systolic Dysfunction
13%
Sarcoma
13%
Capecitabine
13%
Fluorouracil
13%
Androgen
13%
Colorectal Cancer
13%
Recurrent Disease
13%
Systolic Heart Failure
13%
Direct Oral Anticoagulant
13%
Concurrent Infection
13%
Coronavirinae
13%
Doxorubicin
13%
Virus Infection
13%
Galectin 3
13%
Anticoagulation Therapy
12%
Antivitamin K
10%
Brain Natriuretic Peptide
9%
Creatinine
9%
Sodium Glucose Cotransporter 2 Inhibitor
9%
Apixaban
7%
Copeptin
7%
Prevalence
7%
Ischemic Heart Disease
6%
Mineralocorticoid Antagonist
6%
Drug-Drug Interaction
6%
Angiotensin Receptor
6%
Renin-Angiotensin System Inhibitor
6%
Enkephalinase Inhibitor
6%
Beta Adrenergic Receptor Blocking Agent
6%
Symptom
5%
